TScan Therapeutics, Inc. (TCRX) stock
TCRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 4/3089% below fair value
$0.15−0.00 (-1.72%)
Close on Nov 18, 2026Market cap $10.06MP/E –Yield –
TScan Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
TScan Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$120.54M. For fiscal 2025 it was -$135.81M. The highest annual figure on record is -$26.23M in fiscal 2020.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$135.81M | – |
| FY2024 | Dec 31, 2024 | -$134.82M | – |
| FY2023 | Dec 31, 2023 | -$93.46M | – |
| FY2022 | Dec 31, 2022 | -$66.64M | – |
| FY2021 | Dec 31, 2021 | -$48.64M | – |
| FY2020 | Dec 31, 2020 | -$26.23M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$30.49M | – |
| Q1 FY2026 | Mar 31, 2026 | -$29.14M | – |
| Q4 FY2025 | Dec 31, 2025 | -$23.86M | – |
| Q3 FY2025 | Sep 30, 2025 | -$37.05M | – |
| Q2 FY2025 | Jun 30, 2025 | -$38.65M | – |
| Q1 FY2025 | Mar 31, 2025 | -$36.25M | – |
| Q4 FY2024 | Dec 31, 2024 | -$36.71M | – |
| Q3 FY2024 | Sep 30, 2024 | -$32.62M | – |
| Q2 FY2024 | Jun 30, 2024 | -$34.11M | – |
| Q1 FY2024 | Mar 31, 2024 | -$31.37M | – |
| Q4 FY2023 | Dec 31, 2023 | -$21.36M | – |
| Q3 FY2023 | Sep 30, 2023 | -$24.75M | – |
| Q2 FY2023 | Jun 30, 2023 | -$24.61M | – |
| Q1 FY2023 | Mar 31, 2023 | -$22.74M | – |
| Q4 FY2022 | Dec 31, 2022 | -$18.65M | – |
| Q3 FY2022 | Sep 30, 2022 | -$16.58M | – |
| Q2 FY2022 | Jun 30, 2022 | -$15.25M | – |
| Q1 FY2022 | Mar 31, 2022 | -$16.16M | – |
| Q4 FY2021 | Dec 31, 2021 | -$14.20M | – |
| Q3 FY2021 | Sep 30, 2021 | -$15.84M | – |
| Q2 FY2021 | Jun 30, 2021 | -$10.68M | – |
| Q1 FY2021 | Mar 31, 2021 | -$7.92M | – |
| Q4 FY2020 | Dec 31, 2020 | -$7.81M | – |
| Q3 FY2020 | Sep 30, 2020 | -$7.17M | – |
| Q2 FY2020 | Jun 30, 2020 | -$5.62M | – |
See a number that looks wrong?